On October 28, 2026, a Victorian coroner signed off on a finding that most people in this space had been expecting to read about one day: a death caused by a peptide injection. Richard Norton, the 75-year-old martial artist, stuntman and actor, died at the Alfred Hospital in Melbourne on March 30, 2025, two days after injecting CJC-1295 and ipamorelin. Within a day the story was everywhere, and US searches for "actor dies after injecting peptides" and "richard norton peptides" went from nothing to breakout.
Most of the coverage got the headline right and the detail wrong. This was not a gray-market vial from a website. It was a prescribed, pharmacy-compounded product, used under a doctor's care, and the cause was not an overdose in the usual sense. We read the coroner's 13-page finding in full. Here is what it says, what it does not say, and what it means if you use this stack. Let's dive in.
TLDR
What happened? Richard Norton collapsed at home within about ten minutes of his second CJC-1295/ipamorelin injection of the day, went into cardiac arrest, and died two days later. The coroner found the injection "caused an anaphylactic reaction which in turn led to cardiac arrest."
Cause of death (official): 1(a) complications of an out-of-hospital cardiac arrest; 1(b) anaphylaxis; contributing: asthma and hypertrophic cardiomyopathy. The forensic pathologist found evidence of anaphylaxis at autopsy.
The dose: He was prescribed one 0.1 mL injection on weekday evenings. He told a nurse that afternoon he had been taking double, and his wife told doctors he had been injecting twice a day.
The warning signs: Hospital records show local redness and swelling from his first injection, whole-body flushing for the last few days, and on the final morning flushing, chest tightness and shortness of breath that settled with his asthma inhaler.
Legal Status (October 2026): In Australia both peptides are unapproved, prescription-only (Schedule 4) medicines; the coroner recommended the TGA consider moving them to Schedule 10, a ban on human use outside research. In the US neither can lawfully be compounded, and neither is among the six peptides in HHS's October 2026 interim policy.
What the Coroner Found
The finding (COR 2025 001710, Coroner David Ryan) is a finding without inquest, built from medical records, the autopsy, an Australian Health Practitioner Regulation Agency (AHPRA) investigation and a statement from the Therapeutic Goods Administration (TGA). The timeline is short.
| Date | What happened |
|---|---|
| Before March 2025 | A different practitioner had prescribed him BPC-157 with thymosin beta-4, CJC-1295 with ipamorelin, and TB-500. He reported they helped with fatigue, recovery, shoulder pain and muscle loss. |
| March 11 and 15, 2025 | A new doctor took his history, ran blood tests and had him sign a peptide consent form. Anaphylaxis was listed on it as a risk of CJC-1295/ipamorelin. |
| March 19 | After more bloods and a CT coronary calcium score, he was prescribed a CJC-1295/ipamorelin "2000mcg solution", 0.1 mL under the skin in the evening, Monday to Friday, made by a licensed compounding pharmacy in Queensland. |
| March 25 | He told the doctor he felt good and his symptoms were improving. |
| March 28, morning | After an injection, whole-body flushing, chest tightness and shortness of breath, relieved by his Ventolin. |
| March 28, 4 pm | He asked the clinic nurse to replace a vial he had broken, reported no side effects, and said he had been taking double the prescribed dose. He was told to go back to the prescribed dose from the next week. The doctor authorised the replacement by phone and prescribed two more peptides. |
| March 28, 9 pm | Second injection of the day. He said he felt hot and flushed, then collapsed. Paramedics found him in cardiac arrest; his heart was restarted at 9.55 pm. |
| March 30 | He died at the Alfred Hospital of brain injury, bowel ischaemia and heart-muscle damage caused by the arrest. |
At the hospital his tryptase was raised, a marker released when mast cells empty out during an allergic reaction. At autopsy the pathologist found evidence of anaphylaxis and, given the timing, favoured the peptide injections as its cause. He also found hypertrophic cardiomyopathy, a thickened heart muscle that raises the risk of fatal rhythms, and judged it and Norton's asthma could each have contributed. The peptides themselves could not be detected in post-mortem toxicology, because routine testing cannot find them.
The official cause is anaphylaxis leading to cardiac arrest, with a heart condition and asthma making it more dangerous. It is not a growth-hormone overdose, and it is not a contaminated research vial.
How Can a Peptide Injection Cause Anaphylaxis?
Anaphylaxis is a whole-body allergic reaction. Mast cells in the airways, skin and gut dump histamine and other mediators at once; blood vessels open, blood pressure falls, airways tighten, and the heart can stop. The pathologist's description in the finding is the textbook one: it usually follows earlier exposure to the same substance, which Norton had, through his previous prescriber.
Peptides are small proteins, and the immune system can learn to recognise them, especially synthetic ones with modified amino acids. That is exactly the concern the FDA put in writing when it moved both compounds to Category 2 in 2023. It cited immunogenicity for both, impurities for CJC-1295, and "serious adverse events associated with CJC-1295 including increased heart rate and systemic vasodilatory reaction." In the CJC-1295 volunteer trials the FDA later pooled, transient hives affected nearly 30% of people on the drug and flushing with a drop in blood pressure about 30% (Teichman et al., 2006, JCEM, PMID 16352683; FDA PCAC briefing, December 2024).
There is a second route that does not need prior exposure. Some basic peptide drugs switch mast cells on directly through a receptor called MRGPRX2, causing reactions that look like allergy (McNeil et al., 2015, Nature, PMID 25517090). Whether CJC-1295 or ipamorelin act on that receptor has never been tested. We mention it because it is the obvious question, not because anyone has the answer.
Flushing, hives and a drop in blood pressure are recorded side effects of CJC-1295. In Norton's case they escalated over ten days into the reaction that killed him.
What the Reports Say vs What the Finding Says
| Claim in circulation | What the finding actually records | Status |
|---|---|---|
| He died from "unapproved peptides" bought online | Prescribed by a doctor, compounded by a licensed Queensland pharmacy, supplied through the clinic | Incorrect |
| He overdosed | He took more than prescribed, but the mechanism was anaphylaxis, an immune reaction rather than a toxic dose | Partly correct |
| It was a heart attack | Cardiac arrest secondary to anaphylaxis; hypertrophic cardiomyopathy found at autopsy as a contributor | Oversimplified |
| The peptides were confirmed in his blood | Not detectable by post-mortem toxicology; causation rests on timing, symptoms, tryptase and autopsy findings | Incorrect |
| It is the first such case | The TGA has three other anaphylaxis reports with CJC-1295/ipamorelin and six hypersensitivity reports across the peptides he used. It is reported as the first Australian death | Correct, with context |
That TGA figure is the most important number in the document. Three earlier anaphylaxis cases on the same stack, in a country where it can only be obtained on prescription, means this was not a freak event. It also means the signal existed before March 2025.
The Dose: What Was Prescribed vs What Was Taken
The finding records the prescription as a "2000mcg solution" with 0.1 mL per injection. It does not state the volume of the vial, so the per-injection amount is not certain. If the solution held 2,000 mcg per mL, each 0.1 mL injection contained 200 mcg of the blend, which sits squarely in the 100 to 300 mcg range the community uses. We set out the arithmetic on that assumption only.
| Scenario | Volume | U-100 syringe | Amount if 2,000 mcg/mL | Per week |
|---|---|---|---|---|
| As prescribed: evenings, Monday to Friday | 0.1 mL once a day | 10 units | 200 mcg | 1,000 mcg |
| As reported: twice a day | 0.1 mL twice a day | 10 units, twice | 400 mcg a day | Up to 2,800 mcg if daily |
| A misread syringe: 20 units instead of 10 | 0.2 mL | 20 units | 400 mcg | Doubles whatever the schedule is |
Two honest points about this table. First, an allergic reaction is not a dose problem the way toxicity is: people react to tiny amounts of things they are sensitised to. More injections do mean more exposures and more chances to react, and the coroner was right to record the excess. Second, there is no validated dose to compare against. The only clinical doses for either compound are a hospital drip of ipamorelin for bowel recovery and weekly injections of the long-acting CJC-1295 DAC, neither of which looks like this (Beck et al., 2014, Int J Colorectal Dis, PMID 25331030; Teichman et al., 2006). If you are mixing your own, run your numbers through the reconstitution calculator and the dosage calculator rather than guessing in units.
The excess dose is in the finding, but the lesson that transfers is not "stick to 200 mcg". It is that escalating reactions are a stop sign.
The Warning Signs, and What to Do
Read the hospital notes again: "initially local redness and swelling, and subsequently whole of body flushing for the last few days." Then, on the last morning, chest tightness and shortness of breath. Each of those is a hypersensitivity reaction, each was worse than the one before, and the last one before the collapse was treated with an asthma reliever. The clinic heard "no side effects" that afternoon.
If you inject any peptide, these are the signs that mean stop and get seen, not push through:
- Redness or swelling at the site that gets bigger with each injection rather than smaller.
- Flushing, itching or hives beyond the injection site.
- Chest tightness, wheeze, a cough that will not stop, or shortness of breath.
- Swelling of the lips, tongue or throat, a hoarse voice, or trouble swallowing.
- Dizziness, a racing heart, faintness or collapse.
Anaphylaxis needs adrenaline (epinephrine), and fast. Australia's allergy society puts it plainly: it "requires immediate treatment with adrenaline", and delay can be fatal (ASCIA). The World Allergy Organization guidance makes the same point and lists bronchodilators such as salbutamol as second-line, because they ease wheeze but do nothing for falling blood pressure or a swelling throat (Cardona et al., 2020, World Allergy Organization Journal, PMID 33204386). If you have asthma and your inhaler fixes chest tightness after an injection, that is not reassurance. It is a reaction you have just masked. Call emergency services.
And tell your prescriber every reaction, however small. In Norton's case the medical board found the doctor should have called him directly before authorising more product, and cautioned him for not doing so. A reaction the clinic never hears about is one nobody can act on.
The Legal and Regulatory Situation
Australia. CJC-1295, ipamorelin, BPC-157, thymosin beta-4 and TB-500 are not on the Australian Register of Therapeutic Goods. They are unapproved medicines in Schedule 4 of the Poisons Standard, so a doctor can prescribe them through pathways like the Authorised Prescriber Scheme. The coroner said he was "not satisfied that it is appropriate for them to be available to be prescribed" and recommended the TGA review their benefits and risks and consider moving them to Schedule 10, a ban on human use with exceptions for clinical trials. The TGA has said it is considering whether further measures are needed. AHPRA published new guidance in September 2026 saying unapproved and compounded medicines should only be prescribed where there is sufficient evidence or other treatments have failed.
United States. This stack has already been through the FDA's compounding advisory committee and lost: 0 to 12 against ipamorelin in October 2024 and 0 to 13 against CJC-1295 in December 2024 (FDA PCAC minutes). HHS's interim policy of October 27 and 28, 2026 lets pharmacies compound six peptides under ten conditions, among them sourcing from an FDA-registered facility and reporting serious adverse events. Those six are BPC-157, TB-500, KPV, MOTS-c, epitalon and semax. CJC-1295 and ipamorelin are not on it. No US pharmacy has a lawful basis to compound either, whatever a telehealth clinic tells you. Our guide to the temporary sale plan covers how that policy came together.
The product that killed Richard Norton was the regulated version: prescribed, compounded, consented. That is what makes the coroner's recommendation hard to wave away.
The Honest Take
Let's get this straight. One death does not tell you the risk per injection, and nobody can calculate it, because nobody has ever counted how many people use this stack. Norton was 75, had asthma, had an undiagnosed thickened heart muscle, had prior exposure, and was taking more than prescribed. Each of those raised his risk. None of them means it could not happen to you.
What the finding does settle is the mechanism. The fear people usually have about CJC-1295 and ipamorelin is long-term: glucose, IGF-1, cancer, the pituitary. Our CJC-1295 and ipamorelin guide covers those, and they are still unanswered. This death came from the short-term risk, the one that was already on the consent form and already in the FDA's Category 2 entry, and it came from a pharmacy product rather than a dodgy vial. Clean sourcing does not protect you from an allergy to the molecule itself.
If you use this stack anyway: treat any reaction that spreads beyond the injection site as the end of the course, never self-treat chest symptoms after an injection with an inhaler and carry on, report every reaction to whoever prescribed it, and do not increase your dose on your own. That is the whole of what this case can teach, and it is enough.
FAQ
How did Richard Norton die?
The coroner found he had an anaphylactic reaction to an injection of CJC-1295/ipamorelin on the evening of March 28, 2025, which caused a cardiac arrest at home. He was resuscitated but died at the Alfred Hospital on March 30. Asthma and hypertrophic cardiomyopathy were listed as contributing.
Which peptides did Richard Norton take?
The injection linked to his death was a compounded CJC-1295/ipamorelin blend. He had previously used BPC-157 with thymosin beta-4 and TB-500 from another prescriber, and those two were prescribed again on his last day; a sealed vial of BPC-157/thymosin beta-4 was found unused.
Did he buy the peptides online?
No. A doctor prescribed them after blood tests, a heart scan and a signed consent form, and a licensed compounding pharmacy in Queensland made them. That is one of the most misreported details of the case.
Was it an overdose?
He was taking about double the prescribed amount, and the coroner recorded that. But anaphylaxis is an immune reaction, not a toxic dose, and it can follow a small amount of something you are sensitised to. More injections meant more exposures, which is why the excess matters.
Can CJC-1295 or ipamorelin cause anaphylaxis?
Yes. It was listed on his consent form, the TGA holds three other anaphylaxis reports for the stack, and the CJC-1295 volunteer trials recorded hives and flushing with low blood pressure in roughly 30% of participants. How often it happens is unknown.
What are the signs of a peptide allergic reaction?
Injection-site swelling that gets worse each time, flushing, itching or hives elsewhere on the body, chest tightness, wheeze, shortness of breath, throat or tongue swelling, dizziness and collapse. Anything beyond the injection site is a reason to stop and see a doctor; breathing trouble or faintness is an emergency.
Are peptide injections safe?
It depends on the peptide, and for most of the ones sold for wellness, nobody has run the studies to say. The medical board's expert in this case found "insufficient evidence" that CJC-1295/ipamorelin is safe, effective or beneficial for human use, which matches what the FDA's committee concluded in 2024.
Is CJC-1295/ipamorelin legal in Australia?
It is an unapproved, prescription-only medicine, so a doctor can prescribe it through specific pathways but it cannot be sold freely. The coroner has recommended the TGA consider a Schedule 10 ban on human use outside research, and the TGA says it is considering further measures.
Is CJC-1295/ipamorelin legal in the US?
It is not approved, and the FDA's advisory committee voted against both compounds in 2024, so pharmacies cannot lawfully compound them. They are not among the six peptides covered by HHS's October 2026 interim compounding policy.
Why are people suddenly searching "actor dies from peptides"?
The coroner's finding was signed on October 28, 2026 and reported worldwide the next day, the same week HHS announced it would let US pharmacies compound six other peptides. The two stories landed together, and the searches followed both.
Resources
Coroners Court of Victoria (2026), Finding into death without inquest, Richard John Norton, COR 2025 001710, Coroner David Ryan, signed October 28, 2026 — https://www.coronerscourt.vic.gov.au/sites/default/files/COR%202025%20001710%20Form%2038%20-%20Finding%20into%20Death%20without%20Inquest_Signed.pdf
ABC News (2026), Coroner recommends TGA review peptide restrictions after Australian actor's death, including the TGA's response — https://www.abc.net.au/news/2026-10-29/victoria-peptide-death-coroners-report-richard-norton/107320590
The Nightly (2026), Aussie actor and stuntman Richard Norton's death linked to unapproved peptides — https://thenightly.com.au/culture/aussie-actor-and-stuntman-richard-nortons-death-linked-to-unapproved-peptides-c-23087814
Teichman et al. (2006), Journal of Clinical Endocrinology and Metabolism, CJC-1295 DAC ascending-dose trials in healthy adults — https://pubmed.ncbi.nlm.nih.gov/16352683/
Raun et al. (1998), European Journal of Endocrinology, ipamorelin discovery and selectivity — https://pubmed.ncbi.nlm.nih.gov/9849822/
Beck et al. (2014), International Journal of Colorectal Disease, ipamorelin for postoperative ileus, 117 patients — https://pubmed.ncbi.nlm.nih.gov/25331030/
McNeil et al. (2015), Nature, MRGPRX2 as the mast-cell receptor behind pseudo-allergic reactions to peptide drugs — https://pubmed.ncbi.nlm.nih.gov/25517090/
Cardona et al. (2020), World Allergy Organization Journal, World Allergy Organization anaphylaxis guidance 2020 — https://pubmed.ncbi.nlm.nih.gov/33204386/
ASCIA (Australasian Society of Clinical Immunology and Allergy), Anaphylaxis, patient information — https://www.allergy.org.au/patients/about-allergy/anaphylaxis
FDA (2026), Safety risks associated with certain bulk drug substances nominated for compounding, Category 2 entries for CJC-1295 and ipamorelin — https://www.fda.gov/drugs/human-drug-compounding/safety-risks-associated-certain-bulk-drug-substances-nominated-use-compounding
FDA (2024), Briefing document for the October 29, 2024 Pharmacy Compounding Advisory Committee, ipamorelin — https://www.fda.gov/media/182088/download
FDA (2025), Final summary minutes of the December 4, 2024 PCAC meeting, CJC-1295 votes — https://www.fda.gov/media/185642/download
AHPRA (2026), Prescribing off-label, unapproved or compounded medicines, practitioner guidance — https://www.ahpra.gov.au/Resources/Prescribing-off-label-unapproved-or-compounded-medicines
RAPS (2026), HHS will permit compounding of six peptides ahead of formal rulemaking — https://www.raps.org/resource/hhs-will-permit-compounding-of-six-peptides-ahead-of-formal-rulemaking.html
AJMC (2026), 5 things to know about HHS's interim peptide compounding policy — https://www.ajmc.com/view/5-things-to-know-about-hhs-s-interim-peptide-compounding-policy
ONPEPS peptide library, CJC-1295 entry with sourcing and cost pages — https://www.onpeps.com/peptides/cjc-1295
ONPEPS peptide library, ipamorelin entry with sourcing and cost pages — https://www.onpeps.com/peptides/ipamorelin
